Automated Reminders and Physician Notification to Promote Immunosuppression Adherence Among Kidney Transplant Recipients: A Randomized Trial

Background: Immunosuppression nonadherence increases the risk for kidney transplant loss after transplantation. Wireless-enabled pill bottles have created the opportunity to monitor medication adherence in real time. Reminders may help patients with poor memory or organization. Provision of adherence data to providers may motivate patients to improve adherence and help providers identify adherence barriers. Study Design: Randomized controlled trial. Setting & Participants: Kidney transplant recipients (n = 120) at a single center. Intervention: Participants were provided wireless pill bottles to store tacrolimus and record bottle openings. Participants were randomly assigned 1:1:1 to adherence monitoring with customized reminders (including alarms, texts, telephone calls, and/or e-mails), monitoring with customized reminders plus provider notification (every 2 weeks, providers received notification if adherence decreased to <90% during that period), or wireless pill bottle use alone (control). Outcomes: The main outcome was bottle-measured tacrolimus adherence during the last 90 days of the 180-day trial. A secondary outcome was tacrolimus whole-blood concentrations at routine clinical visits. Measurements: Adherence for the primary outcome was assessed via wireless pill bottle openings. Results: Mean participant age was 50 years; 60% were men,. and 40% were black. Mean adherence was 78%, 88%, and 55% in the reminders, reminders-plus-notification, and control arms (P < 0.001 for comparison of each intervention to control). Mean tacrolimus levels were not significantly different between groups. Limitations: The study did not assess clinical end points. Participants and study coordinators were not blinded to intervention arm. Conclusions: Provider notification and customized reminders appear promising in helping patients achieve better medication adherence, but these strategies require evaluation in trials powered to detect differences in clinical outcomes. (C) 2016 by the National Kidney Foundation, Inc.